Novartis COVID-19 mAb fails to meet clinical trial endpoints

By The Science Advisory Board staff writers

November 6, 2020 -- Novartis has released new data from an interim analysis of its randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of canakinumab (Ilaris), a monoclonal antibody (mAb) in hospitalized patients with COVID-19.

The CAN-COVID trial failed to meet its primary endpoint showing that treatment with Ilaris plus standard of care did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation. The trial also did not meet the second endpoint of reducing the COVID-19-related death rate during the four-week period after treatment.

"Though the CAN-COVID trial did not show the patient benefit we were hoping for, it helps improve the scientific understanding of COVID-19 and the role of interleukin-1β inhibition," said Dr. John Tsai, head of global drug development and chief medical officer for Novartis.

Ilaris binds to and neutralizes interleukin-1 beta (IL-1β), blocking its action. As well as being studied in severe COVID-19, Ilaris is also being investigated for the treatment of a number of other diseases involving inflammation, including non-small cell lung cancer.

The company reports that they will submit the interim analysis to a peer-reviewed journal in the coming weeks.

Novartis acquires Vedere Bio
Novartis has acquired Vedere Bio in a deal that includes that company's lead preclinical intravitreally injected adeno-associated virus gene therapy program,...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter